Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-29T12:13:25.575Z Has data issue: false hasContentIssue false

29 - Mesothelioma

Published online by Cambridge University Press:  23 December 2009

Louise Hanna
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Fergus Macbeth
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

Mesothelioma is a challenging disease for patients, relatives and doctors. It is strongly linked to exposure to asbestos and, despite a ban on the use of asbestos in the 1960s in the UK, its incidence is continuing to rise because of the long latent period between exposure and development of the disease. The incidence of mesothelioma is expected to peak around 2020 (Peto et al., 1995). High-quality clinical research evidence to guide treatment decisions is lacking, and there is an urgent need to identify and evaluate new chemotherapeutic agents and treatment strategies.

Of all mesotheliomas, 94.5% affect the pleura, 5.1% affect the peritoneum and 0.4% affect the pericardium (Yates et al., 1997). Mesotheliomas may also arise in the tunica vaginalis.

Types of pleural tumour

The most common tumours affecting the pleura are metastatic from other sites. Table 29.1 shows the types of tumour that affect the pleura.

Anatomy of the pleurae

The pleurae surround both lungs and each is divided into two parts. The parietal pleura lines the cavity bounded by the thoracic wall, diaphragm and lateral mediastinum. The visceral pleura covers the surface of the lungs and extends into the interlobular fissures. The two layers are separated by a small amount of pleural fluid, which reduces friction during respiration.

The parietal pleura is divided into regions: cervical, costal, diaphragmatic and mediastinal. The costal pleura is supplied by intercostal nerves and is sensitive to pain and touch.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bissett, D., Macbeth, F. R. and Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. (R. Coll. Radiol.), 3, 315–7.CrossRefGoogle ScholarPubMed
Boutin, C., Rey, F. and Viallat, J. R. (1995). Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest, 108, 754–8.CrossRefGoogle ScholarPubMed
British Thoracic Society Statement. (2001). Statement on malignant mesothelioma in the United Kingdom. Thorax, 56, 250–65.CrossRef
Gatta, G., Ciccolallo, L., Kunkler, I.et al. (2006). Survival from rare cancer in adults: a population-based study. Lancet Oncol., 7, 132–40.CrossRefGoogle ScholarPubMed
Hubbard, R. (1997). The aetiology of mesothelioma: are risk factors other than asbestos exposure important?Thorax, 52, 496–7.CrossRefGoogle ScholarPubMed
Jaurand, M. C. and Fleury-Feith, J. (2005). Pathogenesis of malignant pleural mesothelioma. Respirology, 10, 2–8.CrossRefGoogle ScholarPubMed
National Statistics. (2005). Cancer Statistics and Registrations, Series MB1 no. 34. London: Office for National Statistics.
Parker, C. and Neville, E. (2003). Lung cancer 8: Management of malignant mesothelioma. Thorax, 58, 809–13.CrossRefGoogle ScholarPubMed
Patz, E. F., Rusch, V. W. and Heelan, R. (1996). The proposed new international tumour nodes metastases staging system for malignant pleural mesothelioma: application to imaging. Am. J. Roentgen, 166, 323–7.CrossRefGoogle Scholar
Peto, J., Seidman, H. and Selikoff, I. J. (1982). Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br. J. Cancer, 45, 124–35.CrossRefGoogle ScholarPubMed
Peto, J., Hodgson, J. T., Matthews, F. E.et al. (1995). Continuing increase in mesothelioma mortality in Britain. Lancet, 345, 535–9.CrossRefGoogle ScholarPubMed
Rusch, V. W., Rosenzweig, K., Venkatraman, E.et al. (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., 122, 788–95.CrossRefGoogle ScholarPubMed
Senan, S. and Pol, M. (2004). Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. Lung Cancer, 45 (Suppl. 1), S93–6.CrossRefGoogle ScholarPubMed
Sugarbaker, D. J., Jaklitsch, M. T. and Liptay, M. J. (1995). Mesothelioma and radical multimodality therapy: who benefits?Chest, 107, 345S–50S.CrossRefGoogle ScholarPubMed
Sugarbaker, D. J., Garcia, J. P., Richards, W. G.et al. (1996). Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann. Surg., 224, 288–94.CrossRefGoogle ScholarPubMed
Travis, W. D., Colby, T. V., Corrin, B.et al. (1999). Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin, New York: Springer, pp. 51–4.CrossRefGoogle Scholar
Gelder, T., Damhuis, R. A., Hoogsteden, H. C. (1994). Prognostic factors and survival in malignant pleural mesothelioma. Eur. Respir. J., 7, 1035–8.Google ScholarPubMed
Vogelzang, N. J., Rusthoven, J. J., Simanowski, J.et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol., 21, 2636–44.CrossRefGoogle ScholarPubMed
Yates, D. H., Corrin, B., Stidolph, P. N.et al. (1997). Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax, 52, 507–12.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Mesothelioma
    • By Louise Hanna, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Fergus Macbeth, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.030
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Mesothelioma
    • By Louise Hanna, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Fergus Macbeth, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.030
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Mesothelioma
    • By Louise Hanna, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Fergus Macbeth, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.030
Available formats
×